Please login to the form below

Not currently logged in
Email:
Password:

Astellas Pharma Europe appoints Mike Crooks to lead its UK operations

He replaces Amit Makwana, who passed away last year

Mike Crooks - Astellas PharmaAstellas Pharma Europe has promoted Mike Crooks to general manager of its UK affiliate, Astellas Pharma Ltd.

He joined Astellas Pharma Ltd in December 2007 as marketing director and was appointed sales and marketing director for specialist brands in 2010.

Crooks has spent more than 30 years in the pharmaceutical industry, starting as a sales representative with Ciba he subsequently held a number of senior sales and marketing positions at Novartis and Zeneca.

Prior to joining Astellas's UK operations he served at Novo Nordisk as marketing and sales director, diabetes, Northern Europe.

"We are delighted to have Mike leading our UK operations,” Ken Jones, Astellas Pharma Europe's president and CEO, said. “When Mike joined Astellas he brought with him a high level of expertise and has since played a role at Astellas Pharma Ltd in supporting its goals of achieving £100m in sales by March 2010, which is now expected to reach £300m in cumulative sales in 2012.

“With a proven track record in delivering sales, and a wealth of experience, Mike provides the right leadership to deliver on our commercial objectives and will support our commitment to patients and healthcare professionals in the UK."

In his new role Crooks will be responsible for managing and expanding Astellas' UK business, which is based in Staines, Middlesex and currently employs more than 250 people. Its therapy area focus is on transplantation, urology, dermatology, anti-infectives, pain management and, more recently, oncology.

He said: "I am very excited to be heading up Astellas UK. With a strong team, product portfolio and a rich pipeline in phase III development, this marks an important period for the business. Having already established category leadership in urology and transplantation, we are looking to do the same in oncology, reinforcing our commitment to bringing new and effective therapies to market in areas where unmet needs still exist.”

Crooks replaces Amit Makwana, whose unexpected death in June 2011 was a huge blow to his colleagues and many friends in the industry.

19th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics